Pennsylvania Alzheimer’s Treatment Bill Stalls
Proposed legislation to mandate insurance coverage for Alzheimer’s treatments failed to reach a vote before the session concluded.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Should insurance companies be legally required to cover emerging treatments for early-stage Alzheimer's?
Pennsylvania lawmakers did not vote on House Bill 2734 before the 2026 legislative session ended. The bill aimed to require insurance coverage for critical Alzheimer’s disease treatments.
Why it matters
The legislation was intended to reduce the financial strain on families facing neurodegenerative diagnoses. It was introduced late in the term, preventing its passage.
Victoria Bayle, who was diagnosed with early-onset Alzheimer’s at age 46, currently relies on lecanemab, which targets amyloid-beta plaques. House Bill 1754, signed in 2024, previously established mandates for private insurance and Medicaid biomarker testing coverage.
The players
Victoria Bayle
She is an Edinboro resident who received an early-onset Alzheimer’s diagnosis at age 46.
Kyle Mullins
He is a state representative who serves as the primary sponsor for House Bill 2734.
The details
Representative Kyle Mullins sponsored the bill to help patients like Bayle, who is now 51, access expensive treatments. The proposal sought to build upon existing laws that currently cover diagnostic testing but not the therapeutic medications themselves.
Timeline
2020: Representative Mullins' father was diagnosed with ALS.
2024: Victoria Bayle received approval for lecanemab and House Bill 1754 was signed into law.
2025: Representative Mullins' father passed away.
Late 2026: House Bill 2734 was not voted on before the legislative session ended.
2027: Representative Mullins plans to reintroduce House Bill 2734.
Health Landscape
The proposed bill follows the passage of House Bill 1754, which mandated coverage for biomarker testing. This legislative effort marks a continued attempt to integrate neurodegenerative disease care into the standard private insurance and Medicaid frameworks.
The failure of this bill means that access to certain Alzheimer's treatments remains subject to existing, potentially restrictive insurance coverage policies. Patients and families in Pennsylvania will need to continue monitoring future legislative sessions for potential changes to treatment accessibility.
The takeaway
Legislative delays in state capitals can significantly impact the timeline for medical treatment access. Advocates suggest that families affected by neurodegenerative diseases should monitor committee schedules to ensure priority bills move forward in future sessions.
What happens next
Representative Kyle Mullins has committed to reintroducing House Bill 2734 during the 2027 legislative session.
Further reading
For more information on the regional policy landscape, visit the Pennsylvania Alzheimer’s section.
Source note: This article includes information reported by The Morning Call.
Live Poll
Should insurance companies be legally required to cover emerging treatments for early-stage Alzheimer's?
